AR054258A1 - Composiciones farmaceuticas y metodos que comprenden una combinacion de un modulador selectivo de receptores estrogenicos y un inhibidor de aromatasa - Google Patents

Composiciones farmaceuticas y metodos que comprenden una combinacion de un modulador selectivo de receptores estrogenicos y un inhibidor de aromatasa

Info

Publication number: AR054258A1
Authority: AR; Argentina
Prior art keywords: phenyl; acceptable salt; aromatase inhibitor; prodrug; patient
Prior art date: 2005-04-25

Application number

AR20060101616A

Other languages

English (en)

Spanish (es)

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-04-25

Filing date

2006-04-24

Publication date

2007-06-13

2006-04-24 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2007-06-13 Publication of AR054258A1 publication Critical patent/AR054258A1/es

Links

238000000034 method Methods 0.000 title abstract 5
229940122815 Aromatase inhibitor Drugs 0.000 title abstract 4
239000003886 aromatase inhibitor Substances 0.000 title abstract 4
239000008194 pharmaceutical composition Substances 0.000 title abstract 3
150000003839 salts Chemical class 0.000 abstract 5
239000000651 prodrug Substances 0.000 abstract 4
229940002612 prodrug Drugs 0.000 abstract 4
GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical compound C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 abstract 3
208000001132 Osteoporosis Diseases 0.000 abstract 2
CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 abstract 1
GGPPBTSXFROGAE-UHFFFAOYSA-N 4-[(4-bromophenyl)methyl-(1,2,4-triazol-4-yl)amino]benzonitrile Chemical compound C1=CC(Br)=CC=C1CN(N1C=NN=C1)C1=CC=C(C#N)C=C1 GGPPBTSXFROGAE-UHFFFAOYSA-N 0.000 abstract 1
BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 abstract 1
208000010392 Bone Fractures Diseases 0.000 abstract 1
206010006187 Breast cancer Diseases 0.000 abstract 1
208000026310 Breast neoplasm Diseases 0.000 abstract 1
208000036119 Frailty Diseases 0.000 abstract 1
208000029725 Metabolic bone disease Diseases 0.000 abstract 1
208000029549 Muscle injury Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
206010049088 Osteopenia Diseases 0.000 abstract 1
206010033128 Ovarian cancer Diseases 0.000 abstract 1
206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
206010039984 Senile osteoporosis Diseases 0.000 abstract 1
229960003437 aminoglutethimide Drugs 0.000 abstract 1
ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 abstract 1
229960002932 anastrozole Drugs 0.000 abstract 1
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 abstract 1
206010003549 asthenia Diseases 0.000 abstract 1
PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 abstract 1
229950004810 atamestane Drugs 0.000 abstract 1
210000000988 bone and bone Anatomy 0.000 abstract 1
229960000255 exemestane Drugs 0.000 abstract 1
229950011548 fadrozole Drugs 0.000 abstract 1
229950001083 finrozole Drugs 0.000 abstract 1
SLJZVZKQYSKYNV-ZWKOTPCHSA-N finrozole Chemical compound C([C@H](O)[C@@H](C=1C=CC(=CC=1)C#N)N1N=CN=C1)C1=CC=C(F)C=C1 SLJZVZKQYSKYNV-ZWKOTPCHSA-N 0.000 abstract 1
229960004421 formestane Drugs 0.000 abstract 1
OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 abstract 1
229960003881 letrozole Drugs 0.000 abstract 1
HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
208000001685 postmenopausal osteoporosis Diseases 0.000 abstract 1
208000001076 sarcopenia Diseases 0.000 abstract 1
229960001771 vorozole Drugs 0.000 abstract 1
XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Child & Adolescent Psychology (AREA)
Hematology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AR20060101616A 2005-04-25 2006-04-24 Composiciones farmaceuticas y metodos que comprenden una combinacion de un modulador selectivo de receptores estrogenicos y un inhibidor de aromatasa AR054258A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US67480705P	2005-04-25	2005-04-25

Publications (1)

Publication Number	Publication Date
AR054258A1 true AR054258A1 (es)	2007-06-13

Family

ID=36693972

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AR20060101616A AR054258A1 (es)	2005-04-25	2006-04-24	Composiciones farmaceuticas y metodos que comprenden una combinacion de un modulador selectivo de receptores estrogenicos y un inhibidor de aromatasa

Country Status (6)

Country	Link
EP (1)	EP1937251A2 (fr)
JP (1)	JP2006306872A (fr)
AR (1)	AR054258A1 (fr)
CA (1)	CA2605796A1 (fr)
TW (1)	TW200716094A (fr)
WO (1)	WO2006114702A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20090029237A (ko)	2006-06-02	2009-03-20	피어 트리 파머슈티칼스 인코포레이티드	위축성 질염을 치료하는 방법
EP2070943A1 (fr) *	2007-12-14	2009-06-17	Crystal Pharma, S.A.	Procédé de préparation des 6-Alkylidenandrost-1,4-dien-3-ones
JP5777163B2 (ja) *	2009-07-03	2015-09-09	国立研究開発法人理化学研究所	Ｐｅｔ用標識化合物
JP6280501B2 (ja) *	2011-09-08	2018-02-14	メレオバイオファーマ２リミテッド	性腺機能低下症および関連疾患の処置ためのアロマターゼ阻害剤の使用
CA3022377A1 (fr)	2016-04-29	2017-11-02	Board Of Regents, The University Of Texas System	Mesure ciblee de l'activite transcriptionnelle liee aux recepteurs hormonaux

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5552412A (en) *	1995-01-09	1996-09-03	Pfizer Inc	5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
AR034142A1 (es) *	2000-09-08	2004-02-04	Sloan Kettering Inst Cancer	Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion
EP1317270A1 (fr) *	2000-09-08	2003-06-11	Pharmacia Italia S.p.A.	Utilisation d'exemestane comme agent de chimio-prevention
WO2003017973A1 (fr) *	2001-08-31	2003-03-06	Pantarhei Bioscience B.V.	Traitement de troubles gynecologiques benins et vecteur d'administration a cet effet
EP1435967A2 (fr) *	2001-10-10	2004-07-14	Pharmacia Italia S.p.A.	Procedes de prevention et de traitement de la deperdition osseuse avec des composes steroides
TW200526206A (en) *	2004-01-13	2005-08-16	Wyeth Corp	Treatment of aromatase inhibitor therapy-related osteoporosis
CA2586844A1 (fr) *	2004-11-04	2006-05-11	Pfizer Products Inc.	Anticorps ctla-4 et inhibiteur de l'aromatase ou traitement combine du cancer du sein

2006
- 2006-04-13 EP EP06744583A patent/EP1937251A2/fr not_active Withdrawn
- 2006-04-13 WO PCT/IB2006/001040 patent/WO2006114702A2/fr not_active Ceased
- 2006-04-13 CA CA002605796A patent/CA2605796A1/fr not_active Abandoned
- 2006-04-24 AR AR20060101616A patent/AR054258A1/es not_active Application Discontinuation
- 2006-04-24 JP JP2006118713A patent/JP2006306872A/ja active Pending
- 2006-04-24 TW TW095114529A patent/TW200716094A/zh unknown

Also Published As

Publication number	Publication date
TW200716094A (en)	2007-05-01
CA2605796A1 (fr)	2006-11-02
WO2006114702A2 (fr)	2006-11-02
EP1937251A2 (fr)	2008-07-02
JP2006306872A (ja)	2006-11-09
WO2006114702A3 (fr)	2007-01-04

Similar Documents

Publication	Publication Date	Title
JP5480623B2 (ja)	2014-04-23	Ｈｓｐ９０活性を調節するトリアゾール化合物
MX2024001849A (es)	2024-02-29	Antagonista del receptor del factor de liberacion de corticotropina 1 (crf1), formulaciones farmaceuticas y formas solidas del mismo para el tratamiento de hiperplasia suprarrenal congenita.
CY1109860T1 (el)	2014-09-10	Παραγοντες υποδοχεα ισταμινης η3, παρασκευη και θεραπευτικες χρησεις
JP2015500887A5 (fr)	2015-12-17
FR16C0021I2 (fr)	2017-04-14	Azetidines en tant qu'inhibiteurs de mek et leur utilisation pour le traitement des maladies proliferatives
GEP20115213B (en)	2011-05-10	Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
IL182218A0 (en)	2007-09-20	Preparation and use of biphenyl-4-yl-carbonylamino and derivatives for the treatment of obesity
MXPA04002037A (es)	2004-06-07	Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad.
NZ593593A (en)	2013-11-29	Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
RU2014120792A (ru)	2015-12-10	Способ лечения стромальных опухолей желудочно-кишечного тракта
EA200600820A1 (ru)	2006-08-25	Способы лечения, модификации и устранения боли с использованием 1-оксо-2-(2,6-диоксопиперидин-3-ил)-4-метилизоиндолина
EA200970500A1 (ru)	2009-10-30	СОЕДИНЕНИЯ ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА АНДРОГЕНОВ
MX2023001468A (es)	2023-03-03	Tratamiento de cancer de prostata.
JP2010503674A (ja)	2010-02-04	血管形成治療用化合物
BRPI0411324A (pt)	2006-07-25	composições farmacêuticas e métodos de tratamento de resposta mediada por histamina em pacientes
CO5670328A2 (es)	2006-08-31	Composiciones farmaceuticas y procedimientos que comprenden combinaciones de derivados de 2-alquiliden-19-nor-vitamina d y un agonista/antagonista de estrogenos
ATE345790T1 (de)	2006-12-15	Kombination von einem aromatasehemmer mit einem bisphosphonat
EA201000656A1 (ru)	2010-12-30	Аминопроизводные 1,2,4-триазола в качестве модуляторов mglur5
RU2007102274A (ru)	2008-07-27	Пиперазиндионы как антагонисты рецептора окситоцина
JP2007505881A5 (fr)	2007-09-27
RU2006108557A (ru)	2007-09-27	Фармацевтические композиции, включающие в себя сочетания производных 2-алкилиден-19-нор-витамина d и паратиреоидного гормона, и способы (лечения)
DE602006017728D1 (de)	2010-12-02	Krebsbehandlung mittels fts und 2-deoxyglucose
TW200716094A (en)	2007-05-01	Pharmaceutical compositions and methods comprising a combination of a selective estrogen receptor modulator and an aromatase inhibitor
TW200616955A (en)	2006-06-01	Novel tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of g-protein coupled receptors (gpcrs)
MX2022007929A (es)	2022-09-29	Coagonistas de triazol grapados de los receptores de glucagon y glp-1.

Legal Events

Date	Code	Title	Description
2014-12-03	FA	Abandonment or withdrawal